Product Code: LI_195293
Title:
Biomarker Technologies Market by Product (Consumables, and Instruments), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunoassay, and Others), and Application (Drug Discovery, Diagnostics, and Personalized Medicine), and Indication (Cancer, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026.
The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.
Biomarker is a biological marker, which indicates a substance or a physical event. These indicated substances or events can be measured and the measurements can be further used for the detection of diseases, a physiological change, response to a treatment and a psychological condition. Biomarker technologies are different techniques, which are employed for testing various diseases. These technologies employ the use of different products to measure a biomarker. Reagents and assays are used in various biomarker technologies such as next generation sequencing, polymerase chain reaction, and others. These biomarker technologies are used in various fields of science such as drug discovery, diagnostics, and personalized medicine. Majorly biomarkers are used to detect diseases such as cancer, infectious diseases, autoimmune diseases, neurological disorders, and others.
Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.
The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
- Consumables
- Assay
- Reagent
- Instruments
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Immunoassay
- Others
By Application
- Drug Discovery
- Diagnostics
- Personalized Medicine
By Indication
- Cancer
- Infectious Diseases
- Autoimmune Disorders
- Cardiovascular Disorders
- Others
By Region
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT:
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- LI-COR, Inc.
- Merck KGAA
- PERKINELMER INC.
- QIAGEN
- Shimadzu Corporation
- Thermo Fisher Scientific, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN:
(These players are not profiled in the report. The same will be included on request)
- Eurofins Scientific
- Enzo Biochem, Inc.
- EKF Diagnostics Holdings plc
- Myriad Genetics, Inc. (Myriad RBM.).
- Becton, Dickinson and Company
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.2.1. List of key players profiled in the report
- 1.3. Research methodology
- 1.3.1. Primary research
- 1.3.2. Secondary research
- 1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. KEY FINDINGS OF THE STUDY
- 2.2. Key findings
- 2.2.1. Top impacting factors
- 2.2.2. Top investment pockets
- 2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key Forces Shaping Biomarker technologies Industry/Market
- 3.2.1. Moderate bargaining power of supplier
- 3.2.2. Low bargaining power of buyers
- 3.2.3. Low threat of substitutes
- 3.2.4. High intensity of rivalry
- 3.2.5. Low threat of new entrant
- 3.3. Pricing Analysis
- 3.3.1. Pricing Analysis of Biomarker technologies, By Region, 2018 & 2025
- 3.4. Market evolution/Industry roadmap
- 3.5. Value Chain Analysis
- 3.6. Impact of government regulations on global biomarker technologies market
- 3.7. Industry Pain point analysis
- 3.8. Market dynamics
- 3.8.1. Drivers
- 3.8.1.1. Rise in prevalence of various diseases
- 3.8.1.2. Surge in R&D activities in healthcare coupled with rise in adoption of early toxicity testing
- 3.8.1.3. Advantages offered by biomarker in drug development
- 3.8.1.4. Increase in genome mapping programs
- 3.8.2. Restraints
- 3.8.2.1. High initial capital investments required for biomarker discovery
- 3.8.2.2. Lack of awareness regarding the use of biomarker technologies
- 3.8.3. Opportunity
- 3.8.3.1. High potential of the emerging economies
- 3.8.4. Impact Analyses
CHAPTER 4: BIOMARKER TECHNOLOGIES MARKET, BY PRODUCT AND SERVICES
- 4.1. Overview
- 4.2. Consumables
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by type
- 4.2.2.1. Reagents
- 4.2.2.1.1. Market size and forecast
- 4.2.2.2. Assays
- 4.2.2.2.1. Market size and forecast
- 4.2.3. Market size and forecast, by region
- 4.2.4. Market analysis by country
- 4.3. Instruments
- 4.3.1. Key market trends, growth factors, and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market analysis by country
CHAPTER 5: BIOMARKER TECHNOLOGIES MARKET, BY TECHNOLOGY
- 5.1. Overview
- 5.2. Polymerase Chain Reaction (PCR)
- 5.2.1. Market size and forecast, by region
- 5.2.2. Market analysis by country
- 5.3. Next Generation Sequencing (NGS)
- 5.3.1. Market size and forecast, by region
- 5.3.2. Market analysis by country
- 5.4. Immunoassay
- 5.4.1. Market size and forecast, by region
- 5.4.2. Market analysis by country
- 5.5. Others
- 5.5.1. Market size and forecast, by region
- 5.5.2. Market analysis by country
CHAPTER 6: BIOMARKER TECHNOLOGIES MARKET, BY APPLICATION
- 6.1. Overview
- 6.2. Drug Discovery
- 6.2.1. Market size and forecast, by region
- 6.2.2. Market analysis by country
- 6.3. Diagnostics
- 6.3.1. Market size and forecast, by region
- 6.3.2. Market analysis by country
- 6.4. Personalized Medicine
- 6.4.1. Market size and forecast, by region
- 6.4.2. Market analysis by country
CHAPTER 7: BIOMARKER TECHNOLOGIES MARKET, BY INDICATION
- 7.1. Overview
- 7.2. Cancer
- 7.2.1. Market size and forecast, by region
- 7.2.2. Market analysis by country
- 7.3. Infectious Diseases
- 7.3.1. Market size and forecast, by region
- 7.3.2. Market analysis by country
- 7.4. Autoimmune Disorders
- 7.4.1. Market size and forecast, by region
- 7.4.2. Market analysis by country
- 7.5. Cardiovascular Disorders
- 7.5.1. Market size and forecast, by region
- 7.5.2. Market analysis by country
- 7.6. Others
- 7.6.1. Market size and forecast, by region
- 7.6.2. Market analysis by country
CHAPTER 8: BIOMARKER TECHNOLOGIES MARKET, BY REGION
- 8.1. Overview
- 8.2. North America
- 8.2.1. Key market trends and opportunities
- 8.2.2. Market analysis by country
- 8.2.2.1. U.S.
- 8.2.2.1.1. U.S. market size and forecast, by product and services
- 8.2.2.1.2. U.S. market size and forecast, by technology
- 8.2.2.1.3. U.S. market size and forecast, by application
- 8.2.2.1.4. U.S. market size and forecast, by indication
- 8.2.2.2. Canada
- 8.2.2.2.1. Canada market size and forecast, by product and services
- 8.2.2.2.2. Canada market size and forecast, by technology
- 8.2.2.2.3. Canada market size and forecast, by application
- 8.2.2.2.4. Canada market size and forecast, by indication
- 8.2.2.3. Mexico
- 8.2.2.3.1. Mexico market size and forecast, by product and services
- 8.2.2.3.2. Mexico market size and forecast, by technology
- 8.2.2.3.3. Mexico market size and forecast, by application
- 8.2.2.3.4. Mexico market size and forecast, by indication
- 8.2.3. North America market size and forecast, by product and services
- 8.2.4. North America market size and forecast, by technology
- 8.2.5. North America market size and forecast, by application
- 8.2.6. North America market size and forecast, by indication
- 8.3. Europe
- 8.3.1. Key market trends and opportunities
- 8.3.2. Market analysis by country
- 8.3.2.1. Germany
- 8.3.2.1.1. Germany market size and forecast, by product and services
- 8.3.2.1.2. Germany market size and forecast, by technology
- 8.3.2.1.3. Germany market size and forecast, by application
- 8.3.2.1.4. Germany market size and forecast, by indication
- 8.3.2.2. France
- 8.3.2.2.1. France market size and forecast, by product and services
- 8.3.2.2.2. France market size and forecast, by technology
- 8.3.2.2.3. France market size and forecast, by application
- 8.3.2.2.4. France market size and forecast, by indication
- 8.3.2.3. UK
- 8.3.2.3.1. UK market size and forecast, by product and services
- 8.3.2.3.2. UK market size and forecast, by technology
- 8.3.2.3.3. UK market size and forecast, by application
- 8.3.2.3.4. UK market size and forecast, by indication
- 8.3.2.4. Italy
- 8.3.2.4.1. Italy market size and forecast, by product and services
- 8.3.2.4.2. Italy market size and forecast, by technology
- 8.3.2.4.3. Italy market size and forecast, by application
- 8.3.2.4.4. Italy market size and forecast, by indication
- 8.3.2.5. Spain
- 8.3.2.5.1. Spain market size and forecast, by product and services
- 8.3.2.5.2. Spain market size and forecast, by technology
- 8.3.2.5.3. Spain market size and forecast, by application
- 8.3.2.5.4. Spain market size and forecast, by indication
- 8.3.2.6. Rest of Europe
- 8.3.2.6.1. Rest of Europe market size and forecast, by product and services
- 8.3.2.6.2. Rest of Europe market size and forecast, by technology
- 8.3.2.6.3. Rest of Europe market size and forecast, by application
- 8.3.2.6.4. Rest of Europe market size and forecast, by indication
- 8.3.3. Europe market size and forecast, by product and services
- 8.3.4. Europe market size and forecast, by technology
- 8.3.5. Europe market size and forecast, by application
- 8.3.6. Europe market size and forecast, by indication
- 8.4. Asia-Pacific
- 8.4.1. Key market trends and opportunities
- 8.4.2. Market analysis by country
- 8.4.2.1. Japan
- 8.4.2.1.1. Japan market size and forecast, by product and services
- 8.4.2.1.2. Japan market size and forecast, by technology
- 8.4.2.1.3. Japan market size and forecast, by application
- 8.4.2.1.4. Japan market size and forecast, by indication
- 8.4.2.2. China
- 8.4.2.2.1. China market size and forecast, by product and services
- 8.4.2.2.2. China market size and forecast, by technology
- 8.4.2.2.3. China market size and forecast, by application
- 8.4.2.2.4. China market size and forecast, by indication
- 8.4.2.3. Australia
- 8.4.2.3.1. Australia market size and forecast, by product and services
- 8.4.2.3.2. Australia market size and forecast, by technology
- 8.4.2.3.3. Australia market size and forecast, by application
- 8.4.2.3.4. Australia market size and forecast, by indication
- 8.4.2.4. India
- 8.4.2.4.1. India market size and forecast, by product and services
- 8.4.2.4.2. India market size and forecast, by technology
- 8.4.2.4.3. India market size and forecast, by application
- 8.4.2.4.4. India market size and forecast, by indication
- 8.4.2.5. South Korea
- 8.4.2.5.1. South Korea market size and forecast, by product and services
- 8.4.2.5.2. South Korea market size and forecast, by technology
- 8.4.2.5.3. South Korea market size and forecast, by application
- 8.4.2.5.4. South Korea market size and forecast, by indication
- 8.4.2.6. Rest of Asia-Pacific
- 8.4.2.6.1. Rest of Asia-Pacific market size and forecast, by product and services
- 8.4.2.6.2. Rest of Asia-Pacific market size and forecast, by technology
- 8.4.2.6.3. Rest of Asia-Pacific market size and forecast, by application
- 8.4.2.6.4. Rest of Asia-Pacific market size and forecast, by indication
- 8.4.3. Asia-Pacific market size and forecast, by product and services
- 8.4.4. Asia-Pacific market size and forecast, by technology
- 8.4.5. Asia-Pacific market size and forecast, by application
- 8.4.6. Asia-Pacific market size and forecast, by indication
- 8.5. LAMEA
- 8.5.1. Key market trends and opportunities
- 8.5.2. Market analysis by country
- 8.5.2.1. Brazil
- 8.5.2.1.1. Brazil market size and forecast, by product and services
- 8.5.2.1.2. Brazil market size and forecast, by technology
- 8.5.2.1.3. Brazil market size and forecast, by application
- 8.5.2.1.4. Brazil market size and forecast, by indication
- 8.5.2.2. Saudi Arabia
- 8.5.2.2.1. Saudi Arabia market size and forecast, by product and services
- 8.5.2.2.2. Saudi Arabia market size and forecast, by technology
- 8.5.2.2.3. Saudi Arabia market size and forecast, by application
- 8.5.2.2.4. Saudi Arabia market size and forecast, by indication
- 8.5.2.3. South Africa
- 8.5.2.3.1. South Africa market size and forecast, by product and services
- 8.5.2.3.2. South Africa market size and forecast, by technology
- 8.5.2.3.3. South Africa market size and forecast, by application
- 8.5.2.3.4. South Africa market size and forecast, by indication
- 8.5.2.4. Rest of LAMEA
- 8.5.2.4.1. Rest of LAMEA market size and forecast, by product and services
- 8.5.2.4.2. Rest of LAMEA market size and forecast, by technology
- 8.5.2.4.3. Rest of LAMEA market size and forecast, by application
- 8.5.2.4.4. Rest of LAMEA market size and forecast, by indication
- 8.5.3. LAMEA market size and forecast, by product and services
- 8.5.4. LAMEA market size and forecast, by technology
- 8.5.5. LAMEA market size and forecast, by application
- 8.5.6. LAMEA market size and forecast, by indication
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. INTRODUCTION
- 9.1.1. MARKET PLAYER POSITIONING, 2018
- 9.2. MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018 (%)
- 9.3. TOP WINNING STRATEGIES
- 9.4. COMPETITIVE DASHBOARD
- 9.5. COMPETITIVE HEATMAP
CHAPTER 10: COMPANY PROFILES: BIOMARKER TECHNOLOGIES MARKET
- 10.1. AGILENT TECHNOLOGIES, INC.
- 10.1.1. Company overview
- 10.1.2. Company snapshot
- 10.1.3. Operating business segments
- 10.1.4. Product type Portfolio
- 10.1.5. Business performance
- 10.2. BIO-RAD LABORATORIES, INC.
- 10.2.1. Company overview
- 10.2.2. Company snapshot
- 10.2.3. Operating business segments
- 10.2.4. Product type Portfolio
- 10.2.5. Business performance
- 10.2.6. Key strategic moves and developments
- 10.3. F. HOFFMANN-LA ROCHE LTD.
- 10.3.1. Company overview
- 10.3.2. Company snapshot
- 10.3.3. Operating business segments
- 10.3.4. Product portfolio
- 10.3.5. Business performance
- 10.3.6. Key strategic moves and developments
- 10.4. Illumina, Inc.
- 10.4.1. Company overview
- 10.4.2. Company snapshot
- 10.4.3. Operating business segments
- 10.4.4. Product Portfolio
- 10.4.5. Business performance
- 10.5. LI-COR, Inc.
- 10.5.1. Company overview
- 10.5.2. Company snapshot
- 10.5.3. Operating business segments
- 10.5.4. Product portfolio
- 10.6. Merck KGAA
- 10.6.1. Company overview
- 10.6.2. Company snapshot
- 10.6.3. Operating business segments
- 10.6.4. Product portfolio
- 10.6.5. Business performance
- 10.6.6. Key strategic moves and developments
- 10.7. PERKINELMER INC.
- 10.7.1. Company overview
- 10.7.2. Company snapshot
- 10.7.3. Operating business segments
- 10.7.4. Product Portfolio
- 10.7.5. Business performance
- 10.8. QIAGEN N.V.
- 10.8.1. Company overview
- 10.8.2. Company snapshot
- 10.8.3. Product type portfolio
- 10.8.4. Business performance
- 10.9. Shimadzu Corporation
- 10.9.1. Company overview
- 10.9.2. Company snapshot
- 10.9.3. Operating business segments
- 10.9.4. Product portfolio
- 10.9.5. Business performance
- 10.11. Thermo Fisher Scientific, Inc.
- 10.11.1. Company overview
- 10.11.2. Company snapshot
- 10.11.3. Operating business segments
- 10.11.4. Product Portfolio
- 10.11.5. Business performance
- 10.12. Other Key Player Profile
- 10.12.1. Key player snapshot
